Ionis: CARDIO-TTRansform Phase 3 of eplontersen misses primary endpoint vs placebo
Ionis announced the CARDIO-TTRansform Phase 3 trial of eplontersen did not meet its primary composite endpoint of CV mortality and recurrent CV events through Week 140.Key Highlights:Original SEC Filing: IONIS PHARMACEUTICALS INC [ IONS ] - 8-K - Jul. 09, 2026This is an AI-powered summary. It may c…